Business Segments · Investment Income, Dividend
Business Segments — Investment Income, Dividend
Pfizer Business Segments — Investment Income, Dividend increased by 110.3% to $82.00M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ1 2017
Last reportedQ1 2026
How to read this metric
Higher income suggests a robust treasury management strategy or successful strategic minority investments.
Detailed definition
Income derived from financial investments, such as dividends or interest, held by the biopharmaceutical segment. This re...
Peer comparison
Varies significantly based on the company's cash management and strategic investment policies.
Metric ID:
pfe_segment_biopharma_investment_income_dividendHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $39.00M | $82.00M |
| QoQ Change | — | +110.3% |
| YoY Change | — | +110.3% |
Range$39.00M – $82.00M
Avg YoY Growth+110.3%
Median YoY Growth+110.3%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's business segments — investment income, dividend?
- Pfizer (PFE) reported business segments — investment income, dividend of $82.00M in Q1 2026.
- What does business segments — investment income, dividend mean?
- Earnings generated from the biopharma segment's financial investments.